TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04490434
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meloxicam 15mg, qd
Study: NCT02595736
Drug: Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02595736
Drug: LY3200327 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02595736
Drug: LY3200327 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02595736
Drug: Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04147312
Drug: Fufang E'Jiao Jiang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Study: NCT04147312
Drug: placebo containing low-dose fufang E'Jiao Jiang
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
Study: NCT02795390
Drug: Chinese herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02795390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05235191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this arm patients will take placebo tablets (the same number, color and physical aspects as the methadone tablets).
Study: NCT01550419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The smell and shape of placebo are the same as atorvastatin
Study: NCT01945489
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) injected into the detrusor.
Study: NCT00829322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule daily for 14 days, increasing to two capsules daily for 14 days
Study: NCT03509675
Drug: Ibuprofen suspension 5mg/100ml
Normalized name: ibuprofen Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
Study: NCT03509675
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01139281
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
Study: NCT03323528
Drug: Benzalkonium Chloride-Benzocaine Topical
Normalized name: benzalkonium chloride-benzocaine topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
Study: NCT03323528
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day.
Study: NCT02980965
Drug: letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
Study: NCT02980965
Drug: fluorouracil, epirubicin, cyclophosphamide, docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
Study: NCT00275158
Drug: L-Arginine Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04197570
Drug: Opioid Anesthetics
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group description
Study: NCT04197570
Drug: Non Opioid Analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: see arm/group description
Study: NCT04476030
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT04476030
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00445510
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01963390
Drug: Testosterone Therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
Study: NCT02170584
Drug: BIBR 953 ZW IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02170584
Drug: BIBR 953 ZW IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04567316
Drug: [14C]-radiolabelled BI 1358894
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1
Study: NCT00934544
Drug: Best Available Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing and usage per respective package inserts
Study: NCT01660711
Drug: 5 Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg/m2 by continuous intravenous infusion over 46 hours
Study: NCT01660711
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 by IV infusion over 2 hours
Study: NCT01577238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel, daily for 7 days
Study: NCT00748644
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
Study: NCT04560634
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine is administered as a continuous infusion at 0.05 mcg/kg/min and is kept to maintain systolic blood pressure within 90-120% of baseline during spinal anaesthesia. The infusion is started at the same time cerebrospinal fluid is obtained, immediately before injection of spinal medications, through a small-bore tubing connected directly to the peripheral intravenous catheter. It is stopped 5 minutes
Study: NCT02845752
Drug: Placebo Respimat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation spray
Study: NCT00314574
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
Study: NCT00314574
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
Study: NCT00314574
Drug: long-acting beta-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg salmeterol twice daily or 12 µg formoterol twice daily.
Study: NCT00951431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the form of study drug
Study: NCT01334658
Drug: Glucose-bicarbonate-Ringer Lactate (GBRL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study: NCT01373749
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation was performed as the only treatment for PPHN during the whole course.
Study: NCT03172936
Drug: MIW815
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIW 815 (ADU-S100) is a STING agonist
Study: NCT01578928
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02619695
Drug: Fastjel
Normalized name: diphenhydramine citrate / pseudoephedrine hydrochloride Disintegrating Oral Tablet [Benadryl-D Fastmelt Allergy and Sinus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
Study: NCT01869192
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2 d1 q3w
Study: NCT01869192
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2/dose bid x 14d q3w
Study: NCT00640705
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Study: NCT00640705
Drug: Matching placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Study: NCT02462967
Drug: GR-MD-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
Study: NCT02462967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for GR-MD-02
Study: NCT00002524
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002524
Drug: Doxorubicin Hydrochloride (DOX)
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002524
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002524
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002524
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01203072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral tablets, once daily for 2 weeks
Study: NCT01968018
Drug: Tramadol HCI/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
Study: NCT01450410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment will last for 12 weeks.
Study: NCT00378014
Drug: CNI
Normalized name: Acnigel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Study: NCT00654069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every 6 hours for 48 hours
Study: NCT00654069
Drug: Acurox 5/30 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every 6 hours for 48 hours
Study: NCT00654069
Drug: Acurox 7.5/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets every 6 hours for 48 hours
Study: NCT00889343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
Study: NCT00889343
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
Study: NCT01256177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
Study: NCT06419283
Drug: standard treatment with aspirin.
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment with aspirin.
Study: NCT01071928
Drug: ASA404
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
Study: NCT03283020
Drug: RemifentanilMNTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Study: NCT03283020
Drug: PlaceboMNTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Study: NCT02284503
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The subjects will receive intensive Rosuvastatin before and after PCI
Study: NCT04504383
Drug: PN-943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by the oral route BID for the duration of the study.
Study: NCT04504383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by the oral route BID for 12 weeks.
Study: NCT00273728
Drug: hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
Study: NCT01325779
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous heparin 5000 units every 8 hours
Study: NCT00849966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO.
Study: NCT01782651
Drug: Lapatinib plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine
Study: NCT05291364
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml + 2 μg/kg dexmedetomidine diluted in 0.9% sterile saline (total volume 12 ml) on each side
Study: NCT05291364
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Is formed of 20 patients had splanchnic plexus block with 4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml diluted in 0.9% sterile saline (total volume 12 ml) on each side.
Study: NCT01893424
Drug: Sativex buccal spray
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal spray
Study: NCT02388984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
Study: NCT00210314
Drug: high dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00358462
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: two 500mg tablets or four 250mg tablets administered as a single dose
Study: NCT00358462
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one 100mg capsule administered twice daily for seven days
Study: NCT00949624
Drug: CP-868,596
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet 60 mg BID continuous
Study: NCT00949624
Drug: CP-868,596
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet 100 mg BID continuous
Study: NCT00706836
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of matched oral placebo to be administered one hour prior to fMRI scan
Study: NCT01650363
Drug: Homeopathic placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-3 mm small spheric suger pils
Study: NCT02131480
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m²
Study: NCT02736656
Drug: SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01624428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg bid placebo titrated over a 2 week period
Study: NCT01354496
Drug: LY2409021 Reference Form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01354496
Drug: LY2409021 Test-Med Formulation (medium particle size)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01054638
Drug: HAART Treatment
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using pharmacy records, identify all patients with HAART dispensing during baseline \& follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past \& non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), \& Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline \& follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs.
Study: NCT03080103
Drug: Antibiotic-first therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with antibiotics as first-line approach
Study: NCT00972803
Drug: pistacia Mutica extract
Normalized name: Pistacia lentiscus resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
Study: NCT00972803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were asked to use a placebo mouthwash twice a day for 4 days.
Study: NCT03117972
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles
Study: NCT03117972
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles
Study: NCT03117972
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles
Study: NCT03117972
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance chemotherapy
Study: NCT01393743
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00717769
Drug: SUN13834
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose, orally 3 times a day (tid) for 28 days of SUN13834
Study: NCT00717769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally (tid) for 28 days of SUN13834
Study: NCT03400033
Drug: Matching placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
Study: NCT03400033
Drug: Saline vials or bags
Normalized name: Rosula NS Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride saline vials or bags administered by the IV route.
Study: NCT01622946
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
Study: NCT02248090
Drug: AZD9496
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9496
Study: NCT02248090
Drug: AZD9496
Approvals — FDA: no, EMA: no, PMDA: no
Description: If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
Study: NCT03234738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is sterile 0.45% saline randomized 3:1 to receive
Study: NCT01664013
Drug: Nuronox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.